Paired sample analysis of mutations by NGS at screening and end of induction. (A) Ivosidenib-treated patients with a best response of CR/CRi/CRp only, n = 31, Personalis ACE Cancer Panel. (B) Enasidenib-treated patients with a best response of CR/CRi/CRp only, n = 28, Archer VariantPlex Core Myeloid panel. Values under each bar denote the number of patients with a mutation detected at baseline and end of induction, and the mutation clearance rate (%) for each gene.